Compounds > nilvadipine
Page last updated: 2024-11-01

nilvadipine and Acute Confusional Senile Dementia

nilvadipine has been researched along with Acute Confusional Senile Dementia in 12 studies

Research Excerpts

ExcerptRelevanceReference
"This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine."9.27Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018)
"Hypertension in an 83-year-old woman with early Alzheimer disease was treated with a calcium channel blocker, nilvadipine, for 3 months."7.74Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. ( Araki, N; Imabayashi, E; Kuji, I; Matsuda, H; Ohkubo, T; Shimazu, K, 2008)
"Background Hypertension is common among patients with Alzheimer disease."6.90Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( Claassen, JAHR; de Heus, RAA; Donders, R; Lawlor, BA; Olde Rikkert, MGM; Santoso, AMM, 2019)
"Nilvadipine treatment lowered systolic blood pressure (Δ=-11."6.90Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. ( Claassen, JAHR; de Heus, RAA; de Jong, DLK; Donders, R; Günther, M; Lawlor, BA; Olde Rikkert, MGM; Rijpma, A; van Osch, MJP, 2019)
"This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine."5.27Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. ( Adams, J; Aisen, P; Anastasios, O; Banzi, R; Börjesson-Hanson, A; Breuilh, L; Calais, G; Coen, R; Crawford, F; Cregg, F; Daly, L; de la Sayette, V; Dereeper, O; Devendeville, A; Franceschi, M; Frisoni, G; Gaynor, S; Hendrix, S; Howard, R; Kálmán, J; Kennelly, S; Kenny, RA; Konsta, A; Lavenu, I; Lawlor, B; Lucca, U; Molloy, DW; Mullan, M; Nemni, R; Nenopoulou, S; Nobili, F; O'Dwyer, S; Olde Rikkert, MGM; Pakaski, M; Pasquier, F; Riepe, MW; Segurado, R; Sénéchal, O; Sheikhi, A; Taekema, DG; Tsolaki, M; Tsolaki-Tagaraki, F; Verhey, FR; Walsh, C; Zanetti, O, 2018)
"Hypertension in an 83-year-old woman with early Alzheimer disease was treated with a calcium channel blocker, nilvadipine, for 3 months."3.74Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. ( Araki, N; Imabayashi, E; Kuji, I; Matsuda, H; Ohkubo, T; Shimazu, K, 2008)
"Background Hypertension is common among patients with Alzheimer disease."2.90Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. ( Claassen, JAHR; de Heus, RAA; Donders, R; Lawlor, BA; Olde Rikkert, MGM; Santoso, AMM, 2019)
"Nilvadipine treatment lowered systolic blood pressure (Δ=-11."2.90Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. ( Claassen, JAHR; de Heus, RAA; de Jong, DLK; Donders, R; Günther, M; Lawlor, BA; Olde Rikkert, MGM; Rijpma, A; van Osch, MJP, 2019)
"Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer's disease (AD), in hypertensive patients."2.76Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. ( Abdullah, L; Crawford, F; Kennelly, SP; Kenny, RA; Lawlor, BA; Mathura, V; Mullan, M; Paris, D; Parish, J, 2011)
"He was diagnosed as having early Alzheimer's disease, in addition to hypertension and type II diabetes mellitus."1.35[A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists]. ( Akai, T; Hanyu, H; Iwamoto, T; Sakurai, H; Sato, T; Takasaki, A, 2008)
"The development of Alzheimer's disease (AD) is generally thought to correlate with cerebral accumulation of Abeta."1.32Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. ( Crawford, F; Crescentini, R; Humphrey, J; Mullan, M; Paris, D; Patel, N; Quadros, A, 2004)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's8 (66.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
de Heus, RAA3
Olde Rikkert, MGM4
Tully, PJ1
Lawlor, BA4
Claassen, JAHR3
Dyer, AH1
Murphy, C2
Segurado, R4
Lawlor, B5
Kennelly, SP2
Kennelly, S4
Howard, R3
Pasquier, F3
Börjesson-Hanson, A2
Tsolaki, M3
Lucca, U3
Molloy, DW1
Coen, R3
Riepe, MW1
Kálmán, J3
Kenny, RA5
Cregg, F3
O'Dwyer, S3
Walsh, C3
Adams, J3
Banzi, R3
Breuilh, L3
Daly, L3
Hendrix, S1
Aisen, P1
Gaynor, S3
Sheikhi, A1
Taekema, DG1
Verhey, FR1
Nemni, R1
Nobili, F1
Franceschi, M1
Frisoni, G1
Zanetti, O1
Konsta, A1
Anastasios, O1
Nenopoulou, S1
Tsolaki-Tagaraki, F1
Pakaski, M1
Dereeper, O1
de la Sayette, V1
Sénéchal, O1
Lavenu, I1
Devendeville, A1
Calais, G1
Crawford, F6
Mullan, M6
Donders, R2
Santoso, AMM1
de Jong, DLK1
Rijpma, A1
Günther, M1
van Osch, MJP1
Riepe, M2
Wallin, A2
Borjesson, A1
Molloy, W2
Olde Rikkert, M2
Meulenbroek, O1
de Jong, D1
van Spijker, G1
Abdullah, L3
Sato, T1
Hanyu, H1
Akai, T1
Takasaki, A1
Sakurai, H1
Iwamoto, T1
Mathura, V2
Luis, CA1
Mouzon, B1
Paris, D2
Parish, J1
Quadros, A1
Humphrey, J1
Patel, N1
Crescentini, R1
Matsuda, H1
Araki, N1
Kuji, I1
Ohkubo, T1
Imabayashi, E1
Shimazu, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease[NCT02017340]Phase 3511 participants (Actual)Interventional2013-04-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

9 trials available for nilvadipine and Acute Confusional Senile Dementia

ArticleYear
Blood Pressure Variability and Progression of Clinical Alzheimer Disease.
    Hypertension (Dallas, Tex. : 1979), 2019, Volume: 74, Issue:5

    Topics: Aged; Alzheimer Disease; Antihypertensive Agents; Blood Pressure Determination; Cognition Disorders;

2019
Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2020, 04-17, Volume: 75, Issue:5

    Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cholinergic Antagonists; Cognitive Dysfunction; Disabili

2020
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    PLoS medicine, 2018, Volume: 15, Issue:9

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cognitive Dysfunction; Disease

2018
Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension.
    Journal of the American Heart Association, 2019, 05-21, Volume: 8, Issue:10

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Blood Pressure; Calcium Channel

2019
Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease.
    Hypertension (Dallas, Tex. : 1979), 2019, Volume: 74, Issue:2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Cerebrovascular Circulation; D

2019
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
    BMJ open, 2014, Oct-09, Volume: 4, Issue:10

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Calcium Channel Blockers; Double-Blind Method; Europe; F

2014
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flo
    BMJ open, 2016, 07-19, Volume: 6, Issue:7

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E3; Biomarkers; Calcium Channel Blockers;

2016
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
    International journal of geriatric psychiatry, 2012, Volume: 27, Issue:4

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Apolipoprotein E4; Cognition; C

2012
Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.
    International journal of geriatric psychiatry, 2011, Volume: 26, Issue:10

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Blood Pressure; Female; Humans;

2011

Other Studies

3 other studies available for nilvadipine and Acute Confusional Senile Dementia

ArticleYear
[A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists].
    Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2008, Volume: 45, Issue:4

    Topics: Aged; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Calcium

2008
Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.
    Brain research, 2004, Feb-27, Volume: 999, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aorta; Calcium Channel B

2004
Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease.
    Clinical nuclear medicine, 2008, Volume: 33, Issue:1

    Topics: Aged, 80 and over; Alzheimer Disease; Antihypertensive Agents; Cerebrovascular Circulation; Cysteine

2008